MedTrace Logo

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

NCT01577550 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2016-11-16

No results posted yet for this study

Summary

Safety, tolerability and efficacy of BI 655066 in male and female patients with moderate to severe psoriasis.

Conditions

Interventions

DRUG

BI 655066 (very high i.v. dose)

Single very high i.v. dose BI 655066

DRUG

Placebo, i.v.

Single i.v. administration of placebo

DRUG

BI 655066 (high s.c. dose)

Single high s.c. dose BI 655066

DRUG

BI 655066 (low i.v. dose)

Single low i.v. dose BI 655066

DRUG

BI 655066 (high medium i.v. dose)

Single high medium i.v. dose BI 655066

DRUG

BI 655066 (very low i.v. dose)

Single very low i.v. dose BI 655066

DRUG

BI 655066 (low s.c. dose)

Single low s.c. dose BI 655066

DRUG

BI 655066 (high i.v. dose)

Single high i.v. dose BI 655066

DRUG

Placebo, s.c.

Single s.c. administration of placebo

DRUG

BI 655066 (low medium i.v. dose)

Single low medium i.v. dose BI 655066

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-10-31
Completion
2014-05-31

Countries

  • United States
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01577550 on ClinicalTrials.gov